The current drug regulatory system is outdated and relies primarily on a process of premarketing evaluation, followed by periodic reviews of reported adverse events. Current drug evaluation systems do not incorporate the comprehensive evidence accruing over time in clinical practice. This paper proposes an alternative system that better brings together the available information. The current...